Canaccord Genuity retains a constructive outlook on rare earth equities, citing China’s 12-month pause on rare earth export ...
Debiopharm is advancing its ADC platform with a focus on proprietary bispecific ADCs and innovative payloads. By leveraging its proven drug development expertise, the company aims to accelerate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback